TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26773906

Group type: EXPERIMENTAL
Intervention: levomilnacipran ER (40-120mg/d)
Number of subjects: 2666
Study: 24634065

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) delivered in groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 0
Study: 22473809

Group type: EXPERIMENTAL
Intervention: 4g curcumin
Number of subjects: 36

Group type: COMPARATOR
Intervention: 4g placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 8g curcumin (open-label extension)
Number of subjects: 36
Study: 19765815

Group type: EXPERIMENTAL
Intervention: Mefloquine (125 mg)
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: Sulfadoxine (250 mg) plus pyrimethamine (12.5 mg)
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: Chlorproguanil (15 mg) plus dapsone (18.75 mg)
Number of subjects: 2419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone
Number of subjects: 2419
Study: 17188097

Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) curriculum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional curriculum (Control)
Number of subjects: 20
Study: 15492301

Group type: EXPERIMENTAL
Intervention: Resistance training (3 supervised sessions per week for 4 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no alteration in normal activity levels)
Number of subjects: 28
Study: 11208630

Group type: EXPERIMENTAL
Intervention: Regular inhaled albuterol (100 microg per puff, in 2 puffs four times daily)
Number of subjects: 53
Study: 9565263

Group type: EXPERIMENTAL
Intervention: IMZ implants connected by a Dolderbar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transmandibular implant (TMI)
Number of subjects: 0
Study: 8139479

Group type: EXPERIMENTAL
Intervention: Low-fat, low-cholesterol diet (LFD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Higher-fat, higher-cholesterol diet (HFD)
Number of subjects: 19
Study: 3421513

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (0.05 and 0.10 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral atenolol (50 and 100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control period (no atenolol)
Number of subjects: 24
Study: 28500743

Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 505

Group type: COMPARATOR
Intervention: ProGlide
Number of subjects: 505
Study: 26764872

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control
Number of subjects: 320
Study: 25588408

Group type: EXPERIMENTAL
Intervention: Reality Orientation (RO) sessions for 6 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (standard treatment with donepezil only)
Number of subjects: 14
Study: 23084002

Group type: EXPERIMENTAL
Intervention: Optimism manipulation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control manipulation
Number of subjects: 79
Study: 21180675

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (CH) containing 1% chloramine-T
Number of subjects: 30

Group type: COMPARATOR
Intervention: Commercial-brand dentifrice (TR) containing triclosan
Number of subjects: 30
Study: 17318860

Group type: EXPERIMENTAL
Intervention: New adjuvanted hepatitis B vaccine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional vaccine (booster)
Number of subjects: 16
Study: 15100697

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 11350019

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sweat pyridinoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: First morning void urine pyridinoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24-hour urine pyridinoline
Number of subjects: 0
Study: 9680894

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg per day)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg per day)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: both alpha-tocopherol and beta-carotene
Number of subjects: 409

Group type: COMPARATOR
Intervention: placebo capsules
Number of subjects: 409
Study: 7976797

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3069767

Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBY)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Gastroplasty (GPL)
Number of subjects: 51
Study: 4218236

Group type: EXPERIMENTAL
Intervention: Extracellular enzyme from Myxobacter AL-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chitosan
Number of subjects: 0
Study: 30086213

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/d
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 28150423

Group type: EXPERIMENTAL
Intervention: Combination of acetyl hexapeptide‐3 with tripeptide‐10 citrulline (Group G1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tripeptide‐10 citrulline (Group G2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetyl hexapeptide‐3 (Group G3)
Number of subjects: 24
Study: 24042339

Group type: EXPERIMENTAL
Intervention: Spectral training
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Spatial training
Number of subjects: 2
Study: 23904619

Group type: EXPERIMENTAL
Intervention: 2 h spatial learning task in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 d training in a Morris water maze in rats
Number of subjects: 0
Study: 21921843

Group type: EXPERIMENTAL
Intervention: Lipiodol (doxorubicin 30 mg/m plus cisplatin 100 mg/m with lipiodol emulsification)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Solution (doxorubicin 30 mg/m plus cisplatin 100 mg/m without lipiodol emulsification)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Responders (both groups combined)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nonresponders (both groups combined)
Number of subjects: 71
Study: 18701822

Group type: EXPERIMENTAL
Intervention: Commercial clear sealant
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Opaque sealants
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Experimental nanofilled clear sealant
Number of subjects: 166
Study: 16881976

Group type: EXPERIMENTAL
Intervention: CYPHER sirolimus‐eluting stent
Number of subjects: 25
Study: 14695863

Group type: EXPERIMENTAL
Intervention: Single injection of 300,000 units of vitamin D(2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Injected vitamin D(2) plus 1 g/day oral calcium
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 800 units/day oral vitamin D(3) plus 1 g/day calcium
Number of subjects: 150

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 150
Study: 11573063

Group type: EXPERIMENTAL
Intervention: Glucose 33% solution
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Glucose 50% solution
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sucrose 33% solution
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sucrose 50% solution
Number of subjects: 140

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Glucose 5% solution
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 140
Study: 9724481

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) administered by continuous infusion at a dose of 10 to 40 microg/h as tolerated
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 18
Study: 7503821

Group type: EXPERIMENTAL
Intervention: rhDNase once daily
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: rhDNase twice daily
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study: 3057041

Group type: EXPERIMENTAL
Intervention: Azelastine 2.0 mg twice daily
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Azelastine 0.5 mg and 1.0 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Chlorpheniramine 4.0 mg four times daily
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Azelastine (high-dose)
Number of subjects: 155
Study: 4390958

Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexpropranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 31899602

Group type: EXPERIMENTAL
Intervention: Ubrogepant 150 mg daily for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ubrogepant (100-400 mg single and multiple ascending doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30737568

Group type: EXPERIMENTAL
Intervention: Simplified protocol (1-cm-thick slabs)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Standard protocol (slabs + 1-mm-spaced planes)
Number of subjects: 894
Study: 28606652

Group type: EXPERIMENTAL
Intervention: Rocuronium 1mg/kg
Number of subjects: 488

Group type: COMPARATOR
Intervention: Suxamethonium 1mg/kg
Number of subjects: 488
Study: 26440829

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (education about the disease, diet therapy, stress reduction methods, effective cough, breathing exercises, muscle stretching exercises) practiced at home three times per week for 7 weeks.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine visits and weekly telephone follow-up (Control group).
Number of subjects: 66
Study: 23436437

Group type: EXPERIMENTAL
Intervention: N. sativa oil (2.5 mL, two times a day for 8 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (2.5 mL, two times a day for 8 weeks)
Number of subjects: 70
Study: 21472722

Group type: EXPERIMENTAL
Intervention: mailed fecal occult blood test (FOBT) card and instructions on how to complete the test (mailed FOBT only)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: mailed FOBT card and instructions on how to complete the test, telephone reminders, and home visits (mailed FOBT and outreach)
Number of subjects: 501

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: mailed FOBT only and mailed FOBT and outreach
Number of subjects: 501
Study: 19309326

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist (control group) for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 40
Study: 16683383

Group type: COMPARATOR
Intervention: Conventional fractionation radiation therapy (CFRT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Split-course accelerated hyperfractionated schedule (S-AHF)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CFRT plus concomitant chemotherapy (CT)
Number of subjects: 192
Study: 15223884

Group type: EXPERIMENTAL
Intervention: Isometric exercise (ISO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isokinetic eccentric exercise (ECC)
Number of subjects: 20
Study: 11421895

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9241005

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 30
Study: 8279248

Group type: EXPERIMENTAL
Intervention: Diclofenac before surgery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Delayed treatment with Diclofenac
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2897300

Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 12
Study: 30511433

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (IG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 39
Study: 29853843

Group type: EXPERIMENTAL
Intervention: 11-week aerobic exercise intervention
Number of subjects: 28
Study: 27276802

Group type: EXPERIMENTAL
Intervention: Arthroscopic assisted single-bundle ACL reconstruction combined with internal tension-relieving technique (group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Arthroscopic assisted single-bundle ACL reconstruction (group B)
Number of subjects: 51
Study: 24424073

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 5000 IU daily for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of 150,000 IU cholecalciferol
Number of subjects: 0
Study: 22024477

Group type: EXPERIMENTAL
Intervention: Preoperative inhalation of milrinone (Mil group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (NS group)
Number of subjects: 30
Study: 19571633

Group type: EXPERIMENTAL
Intervention: Case management using Resident Assessment Instrument-Home Care (RAI-HC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional intervention group
Number of subjects: 92
Study: 17346715

Group type: EXPERIMENTAL
Intervention: Anti-androgen (cyproterone acetate) plus estrogen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16353851

Group type: EXPERIMENTAL
Intervention: Mapping therapy for sentence production
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5
Study: 12241833

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait and see
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 9748424

Group type: EXPERIMENTAL
Intervention: Motivational dietary intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard dietary intervention
Number of subjects: 121
Study: 8270443

Group type: EXPERIMENTAL
Intervention: External-beam radiation therapy plus 5-fluorouracil (5-FU)
Number of subjects: 87

Group type: COMPARATOR
Intervention: External-beam radiation therapy plus hycanthone (HYC)
Number of subjects: 87
Study: 2913977

Group type: EXPERIMENTAL
Intervention: Low-dose heparin with dihydroergotamine (A)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin with dihydroergotamine (B)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 213
Study: 4601222

Group type: COMPARATOR
Intervention: 26° ‐adapted RSV vaccine (28 children)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo control (25 children)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Temperature-sensitive mutant strain (ts-1) (22 children)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo control (21 children)
Number of subjects: 50
Study: 31174514

Group type: EXPERIMENTAL
Intervention: Screen-Refer-Treat (SRT) model including universal Stage 1 ASD screening, immediate referral to community-based EI program, and provision of evidence-based ASD-specialized treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screen-Refer-Treat (SRT) model
Number of subjects: 0
Study: 28494136

Group type: EXPERIMENTAL
Intervention: TECH (technology-supported)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: STND (standard)
Number of subjects: 96

Group type: COMPARATOR
Intervention: SELF (self-guided)
Number of subjects: 96
Study: 26519046

Group type: EXPERIMENTAL
Intervention: EmotionRegulation (transdiagnostic Internet-based protocol)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study: 23531226

Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity aerobic exercise program (TR, n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-trained group (NT, n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls (C, n = 10)
Number of subjects: 19
Study: 22754060

Group type: EXPERIMENTAL
Intervention: HIV and AIDS training programme (2 days duration)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 103
Study: 19147609

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4570
Study: 17534809

Group type: EXPERIMENTAL
Intervention: Nagahara phaco‐chop maneuver (Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Divide and conquer technique (Group 1)
Number of subjects: 50
Study: 15143716

Group type: EXPERIMENTAL
Intervention: Xuesaitong capsule (PNS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Aspirin (ASP)
Number of subjects: 120
Study: 14999615

Group type: EXPERIMENTAL
Intervention: GBS type V CPS‐tetanus toxoid (TT) vaccine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GBS type V CPS‐cross‐reactive material (CRM(197)) conjugate vaccine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10355575

Group type: EXPERIMENTAL
Intervention: Ibandronate 50 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 5 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 10 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 20 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 50 mg
Number of subjects: 110
Study: 8955653

Group type: EXPERIMENTAL
Intervention: 5‐FU 10 mg/m2 orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5‐FU 10 to 25 mg/m2/d orally for 5 days with 776C85 3.7 mg/m2/d orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 776C85 3.7 mg/m2/d orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5‐FU IV route
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5‐FU oral route
Number of subjects: 12
Study: 1774677

Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lateral condensation plus cementation of a cast gold post
Number of subjects: 32

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 32

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 32
Study: 7043497

Group type: EXPERIMENTAL
Intervention: Neurotropic drug (tamitinol dihydrochloride coated tablets of 300 mg t.i.d.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30916527

Group type: EXPERIMENTAL
Intervention: Wrist joint splinting combined with physical therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 40
Study: 30012193

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise combined with conventional exercise of cardiac rehabilitation (CR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional exercise of cardiac rehabilitation (CR) alone
Number of subjects: 120
Study: 26991616

Group type: EXPERIMENTAL
Intervention: Single-dose group (15 mg/kg TXA before surgery and saline 3 hours later)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 2-dose group (10 mg/kg TXA before and 10 mg/kg TXA 3 hours after surgery)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (saline before and 3 hours after surgery)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Single-dose group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 2-dose group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 24289892

Group type: COMPARATOR
Intervention: Fluoxetine (40mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Saffron (30mg/day)
Number of subjects: 40
Study: 21604039

Group type: EXPERIMENTAL
Intervention: Arthroscopic implant removal
Number of subjects: 29

Group type: COMPARATOR
Intervention: Open implant removal
Number of subjects: 29
Study: 20605097

Group type: EXPERIMENTAL
Intervention: Motorized treadmill walking at 5 speeds
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cross-correlated surrogates
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Two-dimensional ARMA process
Number of subjects: 17
Study: 18019592

Group type: EXPERIMENTAL
Intervention: Exercise (James Cycle Protocol)
Number of subjects: 216
Study: 16282842

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 12168782

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg/day for 10 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 10080416

Group type: EXPERIMENTAL
Intervention: 24-hour continuous electrocardiographic monitoring (VCG)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Admission ECG
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: No ST depression with VCG monitoring
Number of subjects: 308
Study: 7675364

Group type: EXPERIMENTAL
Intervention: 123I‐labelled 15‐(p‐iodo‐phenyl)‐3,R,S‐methylpentadecanoic acid (BMIPP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 123I‐meta‐iodobenzyl guanidine (MIBG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 201Tl/99Tcm‐pyrophosphate (Tl‐PYP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Delayed MIBG
Number of subjects: 15
Study: 31074178

Group type: COMPARATOR
Intervention: Anamorelin 5 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Anamorelin 25 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Anamorelin 25 mg and 50 mg
Number of subjects: 25
Study: 28403895

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 26742380

Group type: EXPERIMENTAL
Intervention: Commercial anti-fogging solution (Ultrastop®)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Baby shampoo solution (Johnson's® no more tear®)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 71